Here’s the latest, publicly reported news on daraxonrasib (RMC-6236) and its Ras/RAS protein target, based on recent coverage and scientific reporting.
What daraxonrasib targets
Daraxonrasib is described as a pan-RAS inhibitor that targets oncogenic RAS proteins, including major KRAS variants (often discussed in the context of KRAS G12X–mutant disease). It has been reported to work by interfering with downstream signaling from RAS.[3][9]
Latest headlines & updates (recent months/this year)
- May 2026 (Phase 1/2 report / early data coverage): Reports say daraxonrasib showed potential to improve outcomes versus standard approaches in RAS-mutant pancreatic cancer, based on Phase 1/2 results led by researchers at MD Anderson (coverage dated May 6–5, 2026).[8][10]
- April 2026 (general news coverage): A media piece highlights continued optimism around daraxonrasib for pancreatic cancer, emphasizing that newer KRAS/RAS-directed agents aim to overcome resistance seen with earlier-generation KRAS drugs.[2]
- Jan 2025 (efficacy/safety in RAS-mutated PDAC, widely covered): An oncology news update discusses daraxonrasib demonstrating efficacy potential in RAS-mutated PDAC at a 300 mg dose, including pharmacodynamic changes assessed via circulating tumor DNA.[3]
- Jun 2025 (regulatory milestone): Coverage notes the FDA granted Breakthrough Therapy designation for daraxonrasib in KRAS G12 mutations in previously treated metastatic pancreatic cancer.[4]
- Nov 2025 (preclinical/biologic follow-up coverage): An EurekAlert-style release highlights newer research using RAS(ON) multi-selective inhibition to block tumor growth and activate immune responses (discussed as groundwork for additional trials).[5]
If you want, I can narrow it further
Are you looking for updates specifically about:
- pancreatic cancer (PDAC),
- KRAS G12X-mutant studies,
- or mechanism / Ras signaling (RAF/MEK/ERK, PI3K/AKT, etc.)?
Tell me which, and I’ll focus on the most relevant “newest” items.
Sources
Daraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.
www.onclive.comThe FDA has granted breakthrough therapy designation to daraxonrasib for metastatic pancreatic cancer with KRAS G12 mutations.
rarecancernews.comKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a wide array of KRAS mutations and shows promise against pancreatic and lung cancers. However, the efficacy and mechanisms of action of daraxonrasib in osteosarcoma (OS) remain unclear. We evaluated the effects of daraxonrasib on the viability,...
journals.plos.orgThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.eurekalert.orgA new drug targeting the KRAS mutation is transforming outcomes for pancreatic cancer patients, potentially opening doors for other cancers.
longevitytoday.comKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a ...
pmc.ncbi.nlm.nih.govNew research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma, an aggressive form of skin cancer with limited treatment options beyond immune checkpoint inhibitors. Results from the study were published in Cancer Immunology Research. It shows the potential for durable responses, laying the groundwork for future clinical trials and a...
www.eurekalert.orgThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.news-medical.netTreatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.
www.onclive.com